At the age of 19 years, treatment with dupilumab, a monoclonal antibody blocking IL-4 and IL-13 signaling, was initiated, leading to a significant improvement of the patient’s eczema, but no effects on asthma control. This evidence concerns the gene IL13 and Eczematoid dermatitis.